Clearly pushed by Sigma (portfolio: +20%), Merck’s sales rushed upwards +21% (organic: +5%) to €3,665m whereas the gross profit margin declined from 68.0% to 64.3%. EBITDA jumped +60% to €1,282m, also benefiting from the sale of the rights to Kuvan®, and net profit attributable to shareholders more than doubled, helped by a slightly lower tax rate. Operating CF did not fully reflect the operating performance (+26% to €352m) as the neutralisation of the gain on disposa
19 May 2016
Healthcare back on track?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthcare back on track?
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
19 May 2016 -
Author:
Martin Schnee -
Pages:
3
Clearly pushed by Sigma (portfolio: +20%), Merck’s sales rushed upwards +21% (organic: +5%) to €3,665m whereas the gross profit margin declined from 68.0% to 64.3%. EBITDA jumped +60% to €1,282m, also benefiting from the sale of the rights to Kuvan®, and net profit attributable to shareholders more than doubled, helped by a slightly lower tax rate. Operating CF did not fully reflect the operating performance (+26% to €352m) as the neutralisation of the gain on disposa